Cryptome to collaborate with IMB
Tuesday, 07 December, 2004
Cryptome (ASX: CRP) has signed a memorandum of understanding with the Institute of Molecular Bioscience (IMB) to collaborate on the identification of cardiovascular therapeutics.
The company will combine the high throughput screening capabilities of Cryptomics platform technology, which is based on the identification of small protein fragments with previously undiscovered therapeutic activity, with the IMB's compound libraries, to identify compounds with therapeutic potential in the treatment of cardiovascular disease.
"Bringing together IMB's novel compound libraries and our screening capabilities will make a powerful combination in a most important clinical area," said Cryptome's acting CEO Prof Mathew Vadas.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
